Overexpression of U three protein 14a (UTP14a) is associated with poor prognosis of esophageal squamous cell carcinoma

Kun-Kun Li1, Cheng-Yi Mao2, Jing-Ge Zhang1, Qiang Ma2, Ying-Jian Wang1, Xue-Hai Liu1, Tao Bao1 & Wei Guo1

1 Department of Thoracic Surgery, Daping Hospital, Army Medical University, Chongqing, China
2 Department of Pathology, Daping Hospital, Army Medical University, Chongqing, China

Keywords
Esophageal squamous cell carcinoma; survival; U three protein 14a.

Abstract
Background: Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive and lethal cancers lacking valid prognostic biomarkers. As an essential component of a large ribonucleoprotein complex, U Three Protein 14a (UTP14a) might play important roles in human tumorigenesis. However, the clinical significance and functions of UTP14a in ESCC still remain unclear.

Methods: From September 2009 to August 2015, 210 patients with ESCC of the thoracic esophagus underwent thoracoscopic esophagectomy in our institute. The corresponding 210 tissue samples and 30 cancer-distant mucosa (CDM) samples were tested for UTP14a expression by immunohistochemical staining. The long-term survival was analyzed by the Kaplan–Meier method and Cox proportional hazards regression analyses. CCK8, cell colony formation, cell cycle, apoptosis, cell invasion, and wound healing assays were carried out with ECA109 cells to evaluate the effects of UTP14a on ESCC in vitro.

Results: UTP14a was positively expressed in 88.1% (185/210) of the ESCC samples. UTP14a expression in ESCC was significantly higher than in CDM, as further confirmed by Western blot analysis. High expression of UTP14a in ESCC correlated significantly with tumor invasive depth (pT stage), which predicts poor disease-free survival and disease-specific survival, as indicated by the log-rank test and Cox proportional hazards regression analysis. Additionally, our in vitro experiments further demonstrated that knockdown of UTP14a inhibits cell proliferation and invasion in ECA109 cells.

Conclusions: Our results suggest that UTP14a is aberrantly expressed in ESCC, plays a critical role in cancer progression and could be a potential prognosis predictor of ESCC.

Key points
Significant findings of the study
High expression of UTP14a in ESCC correlated significantly with tumor invasive depth and predicts poor survival; in vitro experiments demonstrated that UTP14a inhibits cell proliferation and invasion.

What this study adds
The results suggest that UTP14a could be a potential prognosis predictor of ESCC.

Introduction
Esophageal cancer (EC) is one of the most aggressive and lethal cancers in patients, and it ranks seventh in terms of incidence and sixth in mortality globally. The histological type of esophageal cancer most often found in Western countries is adenocarcinoma, whereas in China, EC mainly occurs in the form of esophageal squamous cell carcinoma (ESCC). Although recent improvements in surgical technology and multidisciplinary treatments could result in better outcomes, the five-year overall survival rate of ESCC...
remains low (20.9%–43.5%), because of the high incidence of local recurrence and metastasis; recurrence and metastasis can even occur in the early stages. Numerous molecular and protein abnormalities have been found in the pathogenesis of ESCC. However, disease-specific and effective biomarkers have not yet been found, and sensitive biomarkers, as well as novel therapeutic targets, remain to be identified.

In our previous research, we found that wild-type p53-induced gene 1 (WIG-1) could effectively reverse the malignant phenotype, suppress cell proliferation, and induce G0/G1 cell cycle arrest and apoptosis in EC109 cells under zinc deficiency conditions. Furthermore, by yeast-two-hybrid analysis we showed that U three protein 14a (UTP14a) directly binds to WIG-1; UTP14a might therefore be a direct downstream target of WIG-1 (K.K. Li et al. unpublished data).

UTP14a is an essential component of a large ribonucleoprotein complex bound to the U3 small nucleolar RNA. It plays a key role in ribosome biogenesis and 18S rRNA synthesis. Hu et al. reported that UTP14a is overexpressed in various kinds of tumor cell lines, leading to cell cycle arrest and apoptosis through p53 protein degradation, and moreover, ectopically expressed UTP14a could protect tumor cells from chemotherapeutic drug-induced apoptosis. However, the transcription of UTP14a is not regulated by p53. The expression of UTP14a is upregulated in human hepatocellular carcinoma and colorectal carcinoma, and may be associated with poor prognosis. These previous studies suggest that UTP14a plays important roles in human tumorigenesis.

In this study, we investigated the expression of UTP14a in SCC and cancer-distant mucosa (CDM), evaluated the relationship between UTP14a expression and clinicopathological characteristics and survival time of patients with ESCC, and examined whether UTP14a is a potential prognostic biomarker for ESCC.

Methods

Patients, specimens and cell lines

From September 2009 to August 2015, 210 patients with ESCC of the thoracic esophagus underwent thoracoscopic esophagectomy (McKeown) in the Department of Thoracic Surgery, Daping Hospital, Army Medical University (Chongqing, China). All surgeries were performed by the same surgeon (W.G.). The postoperative TNM stage was classified in accordance with the eighth edition of the American Joint Committee on Cancer (AJCC) staging protocol. The corresponding 210 formalin-fixed and paraffin-embedded tissue samples were obtained from the Department of Pathology. During surgery, routine intraoperative frozen section examination was performed to obtain a negative surgical margin (NE). All NE samples were verified to be tumor-free by hematoxylin and eosin (H&E) staining by a pathologist after surgery; 30 of these matching NE samples were selected and served as a control. The study was approved by the Ethics Committee of Daping Hospital.

Exclusion criteria was as follows: (i) neoadjuvant therapy, (ii) postoperative death (death within 30 days after surgery or before discharge from the hospital), (iii) loss to follow-up, (iv) noncurative (R1 or R2) resection (tumor-free margin <1 mm), and (v) death due to causes unrelated to ESCC.

The esophageal cancer cell line ECA-109 was obtained from GeneChem (Shanghai, China) in 2017. The cell line was tested and authenticated by short tandem repeat (STR) analysis as described in the ANSI Standard (ASN-0002) by the American Type Culture Collection (ATCC) Standards Development Organization (SDO) in 2017.

Tissue microarrays, immunohistochemistry and Western blot analysis

A tissue microarray containing a total of 210 formalin-fixed and paraffin-embedded tissue samples was constructed, and immunohistochemistry (IHC) was performed as previously described. Briefly, 4 μm thick sections were deparaffinized in xylene and gradually rehydrated in alcohol solutions. After normal antigen retrieval, IHC staining using the Histostain-Plus Kit and DAB kit (DKAO/Agilent, Denmark) was performed following the manufacturer’s instructions. Subsequently, rabbit anti-UTP14a polyclonal antibody (1:200, Affinity, USA) was used at 4°C. Slides were counterstained with light hematoxylin, dehydrated, and cover-slipped.

All slides were assessed by two pathologists (Qiang Ma and Chengyi Mao, Department of Pathology, Daping Hospital, Army Medical University) without any knowledge of the clinicopathological features. Disagreements were resolved by discussion. A semiquantitative scoring system in considering the staining intensity and proportion was used to estimate the expression of UTP14a as described previously. Each slide was evaluated by the intensity of the cytoplasmatic staining (no staining = 0, weak staining = 1, moderate staining = 2, and strong staining = 3) and the proportion of stained cells (0% = 0, 1–30% = 1, 31–60% = 2, and 61–100% = 3), and the sum ranging from 0 (the minimum score) to six (the maximum score) was the final immunoreactive score, classified as negative expression (0), weak expression (1–2), moderate expression (3–4), and strong expression (5–6). We considered the final immunoreactive score was 1 or higher to be positive.
Proteins from freshly frozen tissue samples were extracted using the T-PER Tissue Protein Extraction kit (Thermo Scientific, USA), separated on SDS-PAGE (Beyotime, China), and transferred onto a polyvinylidene difluoride (PVDF) membrane (Millipore, USA) for Western blot analysis. The membrane was then incubated with rabbit anti-UTP14a polyclonal antibody (Affinity, US). GAPDH (Cell Signaling Technology, USA) was used as an internal control. Protein bands were analyzed with Quantity One software.

**Quantitative real-time PCR (qRT-PCR) analysis**

Total RNA was extracted from cells using Trizol reagent (Shanghai PuFei, China) and reverse-transcribed into cDNA with the M-MLV reagent kit (Promega, USA). qRT-PCR analysis was conducted with SYBR Master Mixture (Takara, USA) to measure the expression of UTP14a. GAPDH was used as an internal control, and the relative mRNA expression of UTP14a mRNA was calculated using the 2−ΔΔCt method.16

UTP14a primers: forward, 5′-AATAAAACCGCAAGTCG-3′, and reverse, 5′-ACAGGCTTGAGTAAAGG-3′; product size: 218 bp.

GAPDH primers: forward, 5′-TGACCTTCAACAGCAGCACCCCA-3′, and reverse, 5′-CACCCCTGTGTGCTGTAGC-3′; product size: 121 bp.

**Plasmids and transfection of cells**

GV248 lentivirus was used to express small interfering RNAs (siRNAs) targeting the UTP14a sequence (Genbank no. NM_006649) (UTP14a-siRNA lentivirus). A nontargeting sequence was cloned into the GV248 lentivirus (GeneChem, Shanghai, China) to generate the lentiviral vectors. ECA109 cells were infected with UTP14a-siRNA lentivirus and NC lentivirus. The interference efficiency of the template was measured by qRT-PCR.

**Cell colony formation assay and CCK8 assay**

The proliferation of ECA109 cells infected with LV-UTP14A-RNAi lentivirus (KD) or NC lentivirus was assessed by cell colony formation and cell counting kit 8 (CCK8) assays.

In the cell formation assay, ECA109 cells suspended in DMEM (Corning, USA) containing 10% fetal bovine serum were plated in six-well plates at 1000 cells/well. The plates were incubated for 14 days and colonies with more than 50 cells were counted. The cells were then stained by crystal violet dye (Sangon Bio, China) and counted with a microscope. Each sample was done in triplicate, and the experiments were repeated three times.

The CCK8 assay was carried out following the manufacturer’s instructions (Sigma, USA). Absorbance of each well was quantified at 450 nm by an enzyme-linked immunosorbent assay (ELISA) microplate reader, and cell growth was assayed every day for five days.

**PI-FACS cell cycle analysis and apoptosis**

Cells were infected with LV-UTP14A-RNAi lentivirus (KD) or NC lentivirus. The various cell cycle phases were determined using propidium iodide (Sigma, USA). Cell populations in the G0/G1 phase, S phase, and G2/M phase were measured using flow cytometry and plotted against cell volume. Data were reported as mean ± standard deviation of three independent experiments. Cell apoptosis was assayed by staining with Annexin V-APC (eBioscience, USA), following the manufacturer’s instructions, and counting the cells by flow cytometry.

**Cell invasion assay**

Cell invasion was studied by using BioCoat Matrigel Invasion Chambers (Corning, USA). After 72 hours, cells migrating through the membrane were stained by Giemsa (Shanghai Dingguo Bio, China) and counted with a microscope. Nine random visual fields (×200 magnification) were chosen for each membrane, and the results expressed as number of migratory cells per field. Data are reported as the mean ± standard deviation of three independent experiments.

**Celigo wound healing assay**

The Celigo cytomter (Nexcelom, USA) provided a tool to directly measure cell migration for label-free or fluorescently labeled cells. We chose a 96-well format, and the wound was created by a square mask. After 24 hours, the entire well was imaged, and the number of cells or percentage of confluence within the previously cleared region was measured. The migration rate is reported as migrated cell surface area (24 hours)/wound area (0 hours) × 100%. Data are reported as the mean ± standard deviation of five independent experiments.

**Follow-up**

All 210 patients were followed-up in the outpatient clinic after surgery every three months during the first year and after surgery every three months during the first year and...
every six months until the fifth year; subsequent follow-ups were performed annually. The follow-up information was completed until March 2018 or death. The follow-up duration ranged between 3.8 and 99.6 months (median, 36 months). The disease-free survival (DFS) rate was established using the survival from surgery to the date of recurrence. Disease-specific survival (DSS) was established using the survival from surgery to the date of death due to ESCC.

### Statistical analysis

Numerical data are expressed as the mean ± standard deviation. Continuous and categorical variables were compared by using the Student t-test and the χ² test, quantitative variables were compared by one-way analysis of variance (ANOVA). Patient survival curves were constructed by the Kaplan–Meier method. The log-rank test was used to compare survival differences between groups for each variable. Univariate and multivariate Cox proportional hazards regression analyses were performed to identify potential prognostic factors. All statistical calculations were performed using SPSS statistical software, version 22.0 (IBM SPSS, USA). A P-value of <0.05 was considered statistically significant.

### Results

#### UTP14a expression in ESCC and CDM

As shown in Fig 1a–g, in ESCC tissues, UTP14a was mainly located in the cytoplasm of tumor cells, and only a small part was located in the nuclei. UTP14a was positively expressed in 88.1% (185/210) of the ESCC samples. In CDM tissues, UTP14a was also mainly localized in the cytoplasm of squamous epithelial cells, with positive staining occurring in nine

---

**Figure 1** IHC staining and Western blot analysis of UTP14a in esophageal squamous cell carcinoma (ESCC) and CDM tissues. (a–d) Negative to strong UTP14a expression in ESCC tissues. (e–f) Negative-to-moderate UTP14a expression in CDM tissues. (h) Western blot analysis of six pairs of ESCC and CDM tissue. (i) Relative UTP14a protein levels were quantified using Quantity One software.
cases (9/30, 30%). The expression of UTP14a in ESCC was significantly higher than in CDM samples ($P < 0.001$, Table 1). These results were further confirmed by Western blot analysis ($P = 0.002$; Fig 1h,i).

### Relationship between UTP14a expression and clinical characteristics

Among the 210 patients, 164 were male, and the male:female ratio was 3.6:1 (Table 1). Gender, age, smoking history, and body mass index (BMI) were well balanced. High expression of UTP14a in ESCC was significantly correlated with postoperative tumor invasive depth (pT stage) ($P = 0.005$) and advanced TNM stage ($P = 0.001$). However, no significant correlation was found between UTP14a expression and clinical characteristics such as tumor location, differentiation grades, and postoperative lymphatic dissemination stage (pN stage).

### UTP14a expression and survival rates

The DFS rate was 82.1% at one year, 58.4% at three years, 48.1% at five years, and 39.6% at eight years, whereas the

| UTP14a expression | Factor | Total | Negative | Weak | Moderate | Strong | $P$ |
|-------------------|--------|-------|----------|------|----------|--------|-----|
|                   | Gender |       |          |      |          |        |     |
|                   | Male   | 164   | 19       | 38   | 49       | 58     | 0.621* |
|                   | Female | 46    | 6        | 9    | 18       | 13     |     |
|                   | Age (years) |       | 61.2 ± 8.1 | 59.6 ± 9.9 | 62.8 ± 7.3 | 61.6 ± 7.9 | 60.5 ± 8.1 | 0.313# |
|                   | Smoking history |       | 0.624* |
|                   | No     | 68    | 10       | 13   | 24       | 21     |     |
|                   | Yes    | 142   | 15       | 34   | 43       | 50     |     |
|                   | BMI (kg/m²) |       | 21.7 ± 3.0 | 21.4 ± 2.9 | 21.3 ± 2.9 | 22.0 ± 3.5 | 21.7 ± 2.6 | 0.664# |
|                   | Tumor location |       | 0.080* |
|                   | Upper thoracic |       | 42 | 3 | 11 | 12 | 8 |     |
|                   | Middle thoracic |       | 139 | 13 | 30 | 44 | 52 |     |
|                   | Lower thoracic |       | 29 | 9 | 6 | 8 | 11 |     |
|                   | Grade |       |          |      |          |        |     |
|                   | Well differentiated (G1) |       | 0.380* |
|                   | Moderately differentiated (G2) |       | 113 | 12 | 21 | 35 | 45 |     |
|                   | Poorly differentiated (G3) |       | 38 | 6 | 10 | 9 | 13 |     |
|                   | pT   |       |          |      |          |        |     |
|                   | Tis  | 4     | 3        | 0    | 1        | 0      | 0.005* |
|                   | T1   | 5     | 1        | 1    | 3        | 0      |     |
|                   | T2   | 29    | 8        | 7    | 4        | 10     |     |
|                   | T3   | 143   | 11       | 32   | 50       | 50     |     |
|                   | T4   | 29    | 2        | 7    | 9        | 11     |     |
|                   | pN   |       |          |      |          |        |     |
|                   | N0   | 102   | 16       | 24   | 31       | 31     | 0.307* |
|                   | N1   | 66    | 7        | 15   | 19       | 25     |     |
|                   | N2   | 34    | 1        | 7    | 16       | 10     |     |
|                   | N3   | 8     | 1        | 1    | 1        | 5      |     |
|                   | Distant metastasis (M) |       | >0.999* |
|                   | M0   | 210   | 25       | 47   | 67       | 71     |     |
|                   | M1   | 0     | 0        | 0    | 0        | 0      |     |
|                   | pStage |       | 0.001* |
|                   | 0    | 4     | 3        | 0    | 10       | 0      |     |
|                   | I    | 19    | 6        | 5    | 3        | 5      |     |
|                   | II   | 82    | 9        | 15   | 30       | 28     |     |
|                   | III  | 105   | 7        | 27   | 33       | 38     |     |
|                   | Tissue origin |       | <0.001* |
|                   | ESCC | 210   | 25       | 47   | 67       | 71     |     |
|                   | CDM  | 30    | 21       | 5    | 4        | 0      |     |

* T, tumor stage (depth of invasion); N, lymphatic dissemination stage, based on the eighth Edition of the American Joint Committee on Cancer (AJCC) staging protocol.\(^1\)\(^4\) pT, primary tumour; Tis, tumour in situ; N0, no positive lymph nodes; N1, 1–2 positive lymph nodes; N2, 3–6 positive lymph nodes; N3, > 6 positive lymph nodes; ESCC, esophageal squamous cell carcinoma; CDM, cancer distant mucosa. *$x^2$ test; #ANOVA test.
Figure 2: Kaplan–Meier survival curves for (a) DFS and (b) DSS of 210 patients. (c) DFS and (d) DSS of different UTP14a expression classifications. (e,f) Compared with UTP14a negative group, the UTP14a positive group was significantly higher in DFS and DSS ($P = 0.012$ and $P = 0.003$, respectively). Data were compared using the log-rank test.
DSS rate was 90.8% at one year, 63.0% at three years, 51.9% at five years, and 41.5% at eight years (Fig 2a,b). As shown in Fig 2c,d, the DFS and DSS were significantly different among the negative and strong expression of UTP14a (P = 0.035 and P = 0.004, respectively). In Fig 2e, f, compared with UTP14a negative group, UTP14a positive group was significantly higher in DFS and DSS (P = 0.012 and P = 0.003, respectively), and high UTP14a expression may indicate poor prognosis.

Prognostic factors for DFS and DSS are presented in Table 2. Univariate analysis indicated that age, gender, smoking history, BMI, and tumor location did not significantly influence DFS and DSS; only the differentiation grade, pT stage, pN stage, and UTP14a expression were associated with the DFS and DSS rates. Moreover, similar findings were observed after multivariate Cox proportional hazards regression analysis, which demonstrated that the differentiation grade, pT stage, pN stage, and UTP14a expression were significantly correlated with patients’ DFS and DSS; higher expression of UTP14a predicted poorer DFS and DSS.

### Inhibition of UTP14a inhibited cell proliferation and invasion in ECA109 cells

The results of the UTP14a knockdown experiments in ECA109 cells are shown in Fig 3. The interference efficiency of UTP14a-siRNA lentivirus is 74.1% (Fig 3a). The cell proliferation of KD-transfected cells was significantly slower than that of NC-transfected cells according to the CCK8 and cell colony formation assays (Fig 3b,c). PI-FACS cell cycle analysis showed that, after 5 days of cell culture, the proportion of KD cells in the G0/G1 phase was significantly larger, and that in the S phase was significantly smaller, than the respective proportions of NC cells (Fig 3d).

As shown in Fig 3e, after 72 hours, the number of invasive cells in the KD group was significantly lower than that in the NC group (P < 0.001). The results of the cell apoptosis assay, after five days of cell culture, are shown in Fig 3f. Although the percentage of apoptotic KD cells was higher than that of NC cells, all percentages were below five, so no apoptosis occurred in the two groups. The results of the Celigo wound healing assay are shown in Fig 3g. No significant difference was found between the two groups (P = 0.098).

### Discussion

WIG-1, which encodes an RNA zinc finger protein, is known to be a p53 target gene. Our previous research found that WIG-1 could effectively reverse the malignant phenotype, suppress cell proliferation, and induce G0/G1 cell cycle arrest and apoptosis of EC109 cells under zinc deficiency conditions.5,6 These results were confirmed by Bersani et al.18 who suggested that WIG-1 binds to the FAS mRNA 3’-UTR and decreases its stability through AU-rich elements. Knockdown of WIG-1 can increase cell death and reduce cell cycle arrest upon DNA damage. UTP14a was found to interact directly with WIG-1 in a yeast-two-hybrid system and is thought to be a downstream target of WIG-1 (K.K. Li et al., unpublished data). UTP is encoded by U3 snoRNA, which is found predominantly in the nucleolus.19 UTP14 is a subunit of the U3

| Variable                 | For DFS  | Hazard ratio (95% CI for HR) | P     | For DSS  | Hazard ratio (95% CI for HR) | P     |
|--------------------------|---------|-----------------------------|-------|---------|-----------------------------|-------|
| Univariate               |         |                             |       |         |                             |       |
| Gender                   |         | 0.990 (0.615–1.593)         | 0.966 |         | 0.918 (0.557–1.513)         | 0.738 |
| Age                      |         | 1.010 (0.984–1.037)         | 0.453 |         | 1.002 (0.975–1.029)         | 0.904 |
| Smoking history          |         | 0.741 (0.491–1.119)         | 0.154 |         | 0.807 (0.525–1.240)         | 0.328 |
| BMI                      |         | 1.001 (0.932–1.074)         | 0.980 |         | 0.985 (0.915–1.061)         | 0.697 |
| Tumor location           |         | 0.715 (0.501–1.020)         | 0.646 |         | 0.689 (0.474–1.003)         | 0.052 |
| Differential grade       |         | 1.639 (1.199–2.241)         | 0.002 |         | 1.525 (1.106–2.103)         | 0.010 |
| pT stage                 |         | 1.535 (1.245–1.892)         | 0.000 |         | 1.514 (1.216–1.884)         | 0.000 |
| pN stage                 |         | 1.823 (1.473–2.256)         | 0.000 |         | 1.901 (1.528–2.365)         | 0.000 |
| pTNM stage               |         | 1.593 (1.367–1.855)         | 0.000 |         | 1.645 (1.398–1.936)         | 0.000 |
| UTP14a expression         |         | 1.351 (1.096–1.664)         | 0.005 |         | 1.503 (1.197–1.886)         | 0.000 |
| Multivariate*            |         |                             |       |         |                             |       |
| Differential grade       |         | 1.585 (1.139–2.205)         | 0.006 |         | 1.548 (1.110–2.160)         | 0.010 |
| pT stage                 |         | 1.436 (1.140–1.809)         | 0.002 |         | 1.400 (1.097–1.787)         | 0.007 |
| pN stage                 |         | 1.713 (1.368–2.145)         | 0.000 |         | 1.794 (1.423–2.262)         | 0.000 |
| UTP14a expression         |         | 1.316 (1.059–1.635)         | 0.013 |         | 1.461 (1.154–1.849)         | 0.002 |

*Cox proportional hazards regression analysis by step forward. UTP14a expression, U Three Protein 14a expression.
Figure 3  UTP14a knockdown experiments in ECA109 cells. (a) ECA109 cells were infected with UTP14a-siRNA lentivirus (KD) and negative control lentivirus (NC). qRT-PCR results show that the interference efficiency was 74.1% (***P< 0.001). (b) Results of the CCK8 assay. The cell proliferation of KD cells was significantly slower than that of NC cells (day 5, ***P< 0.001). (c) Results of the cell colony formation assay. The cell count in the KD group was significantly lower than in the NC group (**P< 0.01). (d) Results of the PI-FACS cell cycle analysis. After five days of cell culture, the proportion of KD cells in the G0/G1 phase was significantly larger, and that in the S phase was significantly smaller than the respective proportions of NC cells (*P> 0.05, ***P< 0.001). (e) Results of the cell invasion assay. After 72 hours, the number of invasive cells in the KD group was significantly lower than that in the NC group (**P< 0.01). (f) Results of the cell apoptosis assay. After five days of cell culture, the percentage of apoptotic cells in the KD group was higher than in the NC group (**P< 0.01), yet both percentages were below five, so no apoptosis occurred in the two groups. (g) Results of the Celigo wound healing assay. After 24 hours, no significant difference was found between the two groups (*P> 0.05).
containing small subunit (SSU) processome complex, and interacts with the preribosome. As a member of the UTP14 family, UTP14a is also involved in ribosome biogenesis and 18S rRNA synthesis. Some studies found that the expression of UTP14a is upregulated in human hepatocellular carcinoma and colorectal carcinoma, and it may be associated with poor prognosis.

In this study, UTP14a was positively expressed in 88.1% of the ESCC samples, and 30% of CDM samples exhibited positive expression; Western blot analysis further confirmed that the protein levels of UTP14a were significantly higher in ESCC. Nucleolar proteins participate in ribosome biogenesis; some studies further demonstrated that nucleolar proteins may interact with many tumor suppressors and proto-oncogenes, and may be associated with many types of cancer.

In ESCC tissues, UTP14a was mainly located in the cytoplasm of tumor cells and only lowly expressed in the nuclei. The potential roles of UTP14a in ESCC remain unclear.

In our previous research, we found that UTP14a is a downstream molecular target of WIG-1 and may play an important role in the p53 pathway. This was confirmed by Hu et al., who found that UTP14a interacts with p53; overexpression of UTP14a could lead to p53 protein degradation, and knockdown of UTP14a could cause cell cycle arrest and apoptosis in HeLa cells. Zhang et al. found that UTP14a is upregulated in human colorectal cancer tissues. They demonstrated that UTP14a forms a complex with USP36/Fbw7, stabilizes c-Myc in the nucleolus, and inhibits c-Myc degradation; knockdown of UTP14a leads to a decrease in c-Myc levels and inhibits tumor growth. In colorectal cancer cell lines, Liu et al. demonstrated that UTP14a acts as a ubiquitin E3 ligase for tumor suppressor retinoblastoma (RB); overexpression of UTP14a leads to protein degradation of both p53 and RB, and causes cancer cell proliferation.

All 210 patients in this study were operated on by the same surgeon using a uniform surgical approach so that the results were more reliable. The five-year DFS and DSS of these patients were 48.1% and 51.9%, respectively, and the eight-year DFS and DSS were 39.6% and 41.5%, respectively. High expression of UTP14a in ESCC was significantly correlated with the pT stage and pTNM stage; overexpression of UTP14a indicated an increased risk of tumor proliferation and invasion. Meanwhile, from the Kaplan–Meier survival curves and the log-rank test, we found that high UTP14a expression predicts poor DFS and DSS. Data from the Worldwide Esophageal Cancer Collaboration database show that the pTNM stage is strongly associated with survival, and the results of our univariate and multivariate Cox proportional hazards regression analyses further confirmed that UTP14a levels and the pTNM stage are independent predictors of long-term survival.

Furthermore, our in vitro experiments showed that upon knockdown of UTP14a, cell proliferation and cell invasion were decreased significantly. Therefore, UTP14a expression levels might be indicative of the aggressiveness of ESCC, and might be useful as a prognostic marker to predict the occurrence of ESCC and death. We speculate that UTP14a might work as a tumor promoter through the cell proliferation and cell invasion pathways, but this hypothesis requires confirmation by further studies.

Although our samples were retrospectively collected from a single institution, the database in our department and the patient follow-up system were well established, and the surgical procedures, pathologic examinations, and patient follow-up were highly uniform throughout the entire study period. Additionally, all patients enrolled in this study had ESCC and the operations were performed by a single surgeon using a uniform surgical approach, with standard exclusion and inclusion criteria. Therefore, we believe that our results are robust and valid.

In conclusion, our results suggest that UTP14a expression is correlated with tumor proliferation and invasion; higher expression of UTP14a is a predictor of poor prognosis in patients with ESCC. Further studies with larger cohorts are needed to validate our results, and it will be interesting and useful to investigate the underlying mechanisms.

Acknowledgments

We thank Professor Jin Hua and Fan Xiaoqing for their assistance with the Western blot analysis and in vitro experiments, and Professor Xu Yang for reviewing the manuscript.

Disclosure

There were no potential conflicts of interest, including specific financial interests and relationships in our manuscript, and the authors have no conflicts of interest.

References

1 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394–424.
2 Chen W, Zheng R, Baade PD et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66: 115–32.
3 Zeng H, Zheng R, Guo Y a. Cancer survival in China, 2003–2005: A population-based study. Int J Cancer 2015; 136: 1921–30.
4 Li KK, Wang YJ, Liu XH, Tan QY, Jiang YG, Guo W. The effect of postoperative complications on survival of patients after minimally invasive esophagectomy for esophageal cancer. Surg Endosc 2017; 31: 3475–82.

5 Guo W, Zou YB, Jiang YG, Wang RW, Zhao YP, Ma Z. Zinc induces cell cycle arrest and apoptosis by upregulation of WIG-1 in esophageal squamous cancer cell line EC109. Tumour Biol 2011; 32: 801–8.

6 Qiu Y, Zou YB, Li K et al. Effect of altered WIG-1 expression on DDP sensitivity in a DDP-resistant esophageal squamous cancer cell line. Curr Cancer Drug Targets 2012; 12: 950–61.

7 Black JJ, Wang Z, Goering LM, Johnson AW. Utp14 interaction with the small subunit processome. RNA 2018; 24: 1214–28.

8 Zhu J, Liu X, Anjos M, Correll CC, Johnson AW. Utp14 recruits and activates the RNA helicase Dhr1 to undock U3 snRNA from the Preribosome. Mol Cell Biol 2016; 36: 965–78.

9 Hu L, Wang J, Liu Y et al. A small ribosomal subunit (SSU) processome component, the human U3 protein 14A (hUTP14A) binds p53 and promotes p53 degradation. J Biol Chem 2011; 286: 3119–28.

10 Ma T, Lu C, Guo Y, Du X. Human U3 protein 14a plays an anti-apoptotic role in cancer cells. Biol Chem 2017; 398: 1247–57.

11 Zhang J, Guo Y, Du X, Xing B. Does not hUTP14a promoter form a regulation feedback loop with P53? Chin J Cancer Res 2014; 26: 159–65.

12 Zhang JY, Xu D, Liu ZZ, Li Y, Wang LJ, Xing BC. Human U three protein 14a expression is increased in hepatocellular carcinoma and associated with poor prognosis. Chin Med J (Engl) 2017; 130: 470–6.

13 Zhang J, Ren P, Xu D et al. Human UTP14a promotes colorectal cancer progression by forming a positive regulation loop with c-Myc. Cancer Lett 2019; 440–441: 106–15.

14 Rice TW, Ishwaran H, Ferguson MK, Blackstone EH, Goldstraw P. Cancer of the Esophagus and Esophagogastric junction: An eighth edition staging primer. J Thorac Oncol 2017; 12: 36–42.

15 Li K, Wang RW, Jiang YG, Zou YB, Guo W. Overexpression of Sox3 is associated with diminished prognosis in esophageal squamous cell carcinoma. Ann Surg Oncol 2013; 20 (Suppl 3): S459–66.

16 Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2^(-Delta Delta C(T)) method. Methods 2001; 25: 402–8.

17 Li KK, Wang YJ, Liu XH, Wang RW, Jiang YG, Guo W. Propensity-matched analysis comparing survival after hybrid thoracoscopic-laparotomy esophagectomy and complete thoracoscopic-laparoscopic esophagectomy. World J Surg 2019; 43: 853–61.

18 Bersani C, Xu LD, Vilborg A, Lui WO, Wiman KG. Wig-1 regulates cell cycle arrest and cell death through the p53 targets FAS and 14-3-3-sigma. Oncogene 2014; 33: 4407–17.

19 Dragon F, Gallagher JE, Compagnone-Post PA et al. A large nucleolar U3 ribonucleoprotein required for 18S ribosomal RNA biogenesis. Nature 2002; 417: 967–70.

20 Roche B, Arcangioli B, Martienssen R. New roles for dicer in the nucleolus and its relevance to cancer. Cell Cycle 2017; 16: 1643–53.

21 Orsolic I, Jurada D, Pullen N, Oren M, Eliopoulos AG, Volarevic S. The relationship between the nucleolus and cancer: Current evidence and emerging paradigms. Semin Cancer Biol 2016; 37-38: 36–50.

22 Liu H, Wang J, Liu Y et al. Human U3 protein14a is a novel type ubiquitin ligase that binds RB and promotes RB degradation depending on a leucine-rich region. Biochim Biophys Acta Mol Cell Res 2018; 1865: 1611–20.

23 Rice TW, Ishwaran H, Hofstetter WL, Kelsen DP, Apperson-Hansen C, Blackstone EH. Recommendations for pathologic staging (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals. Dis Esophagus 2016; 29: 897–905.